IMMU Mendus AB (publ)

0.3376USD3.430 SEK · STO-4.72%Mkt Cap: 21.70M USDP/E: —

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for t…